This has always been my opinion. MGMT will restructure simply because they do have a product. Maybe that product has a low probability of success but at least it has some success record. This success record could be easily amplified by a take over from another larger phrama. I think it is clear how the pharma industry is going through a lot of change lately with all the aquisitons and cancer is at the heart of what pharma companies are trying to position themselves.
of course no one will take over with ~5B in outstanding hence the request for SEC to revok shares. Furthermore, the 30 something million in debt is simply a joke for a pharma company with a product even in the case of RXPC.
bottom line, this will restructure and make MGMT money along with whoever takes over the ownership. As far as retail shareholdes, they are kinda screwed with that SEC filing.